Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.

Domenica Lorusso,Jean-Pierre Lotz,Philipp Harter,Claire Cropet,María Jesús Rubio Pérez,Christian Schauer,Takashi Matsumoto,Ignace Vergote,Nicoletta Colombo,Trine Jakobi Noettrup,Hugues Bourgeois,Andreas Schnelzer,Sandro Pignata,Y. Garcia,Magali Provansal,Lars Hanker,Dominique Berton,Dirk Bauerschlag,Florence Joly,Isabelle Ray-Coquard

Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.

2020

6039Background: In PAOLA-1/ENGOT-ov25 (NCT02477644), adding the PARP inhibitor olaparib to maintenance bev after first-line platinum-based chemotherapy plus bev led to a statistically significant p...

Keywords:

BRCA2 Mutation
Bevacizumab
newly diagnosed
Oncology
Olaparib
Internal medicine
Medicine
Chemotherapy
Ovarian cancer
Pathology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations